Cannovum AG Launches Medical Cannabis Education Platform


DGAP-News: Cannovum AG / Key word(s): Market launch
09.02.2022 / 08:41
The issuer is solely responsible for the content of this announcement.

Cannovum AG (Dusseldorf, Munich, Hamburg, Berlin stock exchanges, gettex: ISIN DE000A2LQU21) announces the launch of its Medical Training Platform (CME).
It is a complete and free virtual continuing education platform for medical cannabis, in which the medical-therapeutic basics of medical cannabis are scientifically prepared.

The continuing education offer consists of four different areas:

1.) CANNOVUM Webinars: on-demand video courses with experts, which are regularly expanded to include hot topics

2.) CANNOVUM Workshops: personalized workshops for health professionals

3.) CANNOVUM Study Material: brochures and information material for self-study

4.) CANNOVUM Literature: a literature service with collections of current literature and regular study summaries

Cannabis and its effects on the body are still rarely part of medical or pharmaceutical education. Doctors, pharmacists and health professionals must therefore acquire knowledge through continuing education.

“We created Cannovum Medical Education because the subject of cannabis is unfortunately still very stigmatized socially and many patients who could be helped by cannabis therapy do not have access to it. With further education on the medical potential of cannabis, we can reduce bookings and provide a broader understanding of this form of therapy.In this way, we can help doctors, pharmacists and healthcare professionals in particular to improve patient care and provide the best therapy for every patient,” says Pia Marten, CEO of Cannovum AG.

Individual classes are led by Cannovum’s medical advisory board: Dr. med. Dipl.-Chem. Konrad F. Cimander, a renowned expert in the field of addiction medicine and cannabis therapy and Chief Medical Advisor at Cannovum, Priv. Doz. Dr med. dress. Philipp Sewerin, private speaker and specialist in internal medicine and rheumatology, and Dr. Sandra Bütow, head of medical affairs at Cannovum.

Cannovum Medical Education combines sound scientific expertise with the wealth of knowledge gained from many years of experience with cannabis therapies to optimally support healthcare professionals in patient care.


Linda Rasch, IR and PR, Cannovum AG
Telephone +49 30 3982 163 62, [email protected]

Cannovum AG is the first listed medical cannabis company in Germany. The shares are traded on the Düsseldorf, Munich, Berlin, Hamburg and gettex stock exchanges. Through its subsidiary Cannovum Health eG, Cannovum is a fully licensed wholesaler, importer and pharmaceutical manufacturer of high quality medical cannabis products based in Berlin. The company is focused on the importation of high quality cannabinoid products, medical-scientific education and global distribution for simplified and easy access to cannabis therapies.

For more information, visit

09.02.2022 Broadcast of a Corporate News, transmitted by the DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at

Source link


Comments are closed.